E-viri
Recenzirano
-
Paiva, Bruno; Vidriales, María-Belen; Sempere, Amparo; Tarín, Fabián; Colado, Enrique; Benavente, Celina; Cedena, María-Teresa; Sánchez, Joaquín; Caballero-Velazquez, Teresa; Cordón, Lourdes; Garces, Juan-Jose; Simoes, Catia; Martínez-Cuadrón, David; Bernal, Teresa; Botella, Carmen; Grille, Sofia; Serrano, Josefina; Rodríguez-Medina, Carlos; Algarra, Lorenzo; Alonso-Domínguez, Juan-Manuel; Amigo, María-Luz; Barrios, Manuel; García-Boyero, Raimundo; Colorado, Mercedes; Pérez-Oteyza, Jaime; Pérez-Encinas, Manuel; Costilla-Barriga, Lisette; Sayas, María-José; Pérez, Olga; González-Díaz, Marcos; Pérez-Simón, José A; Martínez-López, Joaquín; Sossa, Claudia; Orfao, Alberto; San Miguel, Jesús F; Sanz, Miguel-Ángel; Montesinos, Pau
Leukemia, 08/2021, Letnik: 35, Številka: 8Journal Article
The role of decentralized assessment of measurable residual disease (MRD) for risk stratification in acute myeloid leukemia (AML) remains largely unknown, and so it does which methodological aspects are critical to empower the evaluation of MRD with prognostic significance, particularly if using multiparameter flow cytometry (MFC). We analyzed 1076 AML patients in first remission after induction chemotherapy, in whom MRD was evaluated by MFC in local laboratories of 60 Hospitals participating in the PETHEMA registry. We also conducted a survey on technical aspects of MRD testing to determine the impact of methodological heterogeneity in the prognostic value of MFC. Our results confirmed the recommended cutoff of 0.1% to discriminate patients with significantly different cumulative-incidence of relapse (-CIR- HR:0.71, P < 0.001) and overall survival (HR: 0.73, P = 0.001), but uncovered the limited prognostic value of MFC based MRD in multivariate and recursive partitioning models including other clinical, genetic and treatment related factors. Virtually all aspects related with methodological, interpretation, and reporting of MFC based MRD testing impacted in its ability to discriminate patients with different CIR. Thus, this study demonstrated that "real-world" assessment of MRD using MFC is prognostic in patients at first remission, and urges greater standardization for improved risk-stratification toward clinical decisions in AML.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.